Industry Newsfasn inhibitoracneascletisphase iii

Ascletis Announces Positive Phase III Results For Denifanstat

manilatimes.net

|January 29, 2026

3.6

Relevance Score

Ascletis Announces Positive Phase III Results For Denifanstat

Ascletis reports positive topline Phase III open-label results for denifanstat (ASC40), a once-daily oral FASN inhibitor for acne. The company says denifanstat demonstrated favorable safety and tolerability in the study.

More AI & Data Science News

Tech Services Face Market Contraction in 2026

7.1

Just now

Tech Services Face Market Contraction in 2026

AI Threatens Jobs In Women-Dominated Administrative Roles

8.3

Just now

AI Threatens Jobs In Women-Dominated Administrative Roles

GOG Employee Confirms AI-Generated Sale Artwork

6.1

Back to News Feed

Scoring Rationale

Moderate novelty and segment impact; limited efficacy details and RSS-only source reduce confidence in broader significance.

Sources

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
manilatimes.net
Read Original

Share

Just now

GOG Employee Confirms AI-Generated Sale Artwork

8.1

Just now

Chalmers Seeks Senior Quantum Computing Application Engineer

View All News